Table 1 Patient and disease characteristics (ITT population)
Sequence A (n = 175) | Sequence B (n = 164) | Total (n = 339) | |
|---|---|---|---|
Age in years, mean ± SD | 61.9 ± 8.8 | 62.7 ± 9.2 | 62.3 ± 9.0 |
Female gender, % | 38.3 | 40.9 | 39.5 |
Weight in kg, mean ± SD | 90.1 ± 15.8 | 91.1 ± 15.1 | 90.5 ± 15.5 |
BMI in kg/m2, mean ± SD | 30.9 ± 4.5 | 31.2 ± 4.7 | 31.0 ± 4.6 |
WC in cm, mean ± SD | 106.4 ± 11.7 | 107.2 ± 11.4 | 106.8 ± 11.5 |
Diabetes duration in months, mean ± SD | 115.1 ± 71.3 | 115.2 ± 71.0 | 115.2 ± 71.0 |
Diabetes duration in years, mean ± SD | 9.6 ± 5.9 | 9.6 ± 5.9 | 9.6 ± 5.9 |
HbA1c in %, mean ± SD | 8.17 ± 0.73 | 8.13 ± 0.72 | 8.15 ± 0.72 |
FBG in mmol/L, mean ± SD | 9.24 ± 2.23 | 9.50 ± 2.16 | 9.37 ± 2.19 |
Time since first OHA treatment in months, mean ± SD | 72.8 ± 62.2 | 67.3 ± 55.3 | 70.2 ± 58.9 |
Concomitant disease | |||
Cardiac disorders, % | 28.0 | 23.8 | 26.0 |
Vascular disorders, % | 86.3 | 88.4 | 87.3 |
Renal and urinary disorders, % | 24.6 | 18.3 | 21.5 |
Concomitant oral medication | |||
Metformin, % | 90.9 | 89.6 | 90.3 |
Sulfonylurea, % | 57.7 | 54.9 | 56.3 |
DPP-IV inhibitors, % | 22.3 | 26.2 | 24.2 |